Eli Lilly and Novo Nordisk, two titans of the healthcare industry, have soared to almost legendary status, jointly amassing a market worth close to $1.4 trillion. These firms have carved out significant niches in the lucrative market of glucagon-like peptide 1 (GLP-1) drugs, with Novo Nordisk boasting popular names like Ozempic and Wegovy, and Eli […]
Tag: LLY
The Next Frontier in Obesity Treatment: Who Will Lead the Charge Beyond Eli Lilly and Novo Nordisk?
The weight-loss drug market is currently witnessing an exciting phase with numerous players poised to challenge the dominance of Eli Lilly and Novo Nordisk, the current leaders with their GLP-1 agonist offerings, Zepbound and Wegovy respectively. The rapid advancement of clinical programs across various pharmaceutical companies suggests that the competition is about to intensify, bringing […]
Ozempic face
The term “Ozempic face” refers to the noticeable changes in facial appearance, such as gauntness and increased wrinkling, that some individuals experience after significant weight loss from using drugs like Ozempic and Wegovy. These changes are due to the rapid loss of facial volume and fat. Similarly, “Ozempic butt” describes the sagging and loose skin […]
Misconceptions about these weight loss drugs
According to Dr. Arti Masturzo, the Chief Medical Officer of CCS, there is a concerning trend where patients view GLP-1 weight loss drugs as standalone treatments, which could lead to ignoring potential side effects and long-term consequences. In her interview with The American Journal of Managed Care® (AJMC®), Dr. Masturzo highlighted that while these drugs […]
Ozempic ftw
Elon Musk, CEO of Tesla and SpaceX, has recently brought attention to the growing issue of childhood obesity and potential solutions by showing support for Novo Nordisk’s Ozempic, a GLP-1 agonist traditionally prescribed to manage Type 2 diabetes. His comments have sparked conversation regarding the role that medications like Ozempic could play in addressing this […]
The promise and potential of Artificial Intelligence
In the landscape of modern investing, few topics generate as much interest as the promise and potential of Artificial Intelligence (AI). Richard Carlyle, Equity Investment Director at Capital Group, offers keen insights into the winners and losers in this realm while also providing a global market outlook. As Carlyle observes, the global economy is showing […]